UNZA-UCLMS

Global spread of antibiotic-resistant bacteria and mass-gathering religious events. Zumla A, Azhar EI, Hui DS, Shafi S, Petersen E, Memish ZA. Lancet Infect Dis. 2018 May;18(5):488-490. doi: 10.1016/S1473-3099(18)30242-1.

Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Lancet Infect Dis. 2018 Apr 18.

The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Floyd K, Glaziou P, Zumla A, Raviglione M.

Lancet Respir Med. 2018 Apr;6(4):299-314.

Tuberculosis research and development: seeding the future. Lienhardt C, Zumla A, Gebreselassie N, Frick M, Gray G, Kasaeva T, Raviglione M. Lancet Respir Med. 2018 Apr;6(4):242-244.

B cells or T cells in TB: a continuing conundrum. Maeurer M, Rao M, Zumla A.

Lancet Respir Med. 2018 Apr;6(4):237-238.

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, Mfinanga S, Kapata N, Mwaba P, McHugh TD, Ippolito G, Migliori GB, Maeurer MJ, Zumla A. Lancet Infect Dis. 2018 Mar 23.

Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Walzl G, McNerney R, du Plessis N, Bates M, McHugh TD, Chegou NN, Zumla A. Lancet Infect Dis. 2018 Mar 23. pii: S1473-3099(18)30111-7. doi: 10.1016/S1473-3099(18)30111-7.

Concrete action now: UN High-Level Meeting on Tuberculosis. Herbert N, Sharma V, Masham BS, Sheehan BS, Hauser J, Zumla A. Lancet Infect Dis. 2018 Mar 23. pii: S1473-3099(18)30171-3.

Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 - "Wanted: Leaders for a TB-Free World. You can make history. End TB". Tiberi S, Petersen E, Maeurer M, Ntoumi F, Yeboa-Manu D, Mwaba P, Vilaplana C, Dar O, Bates M, Corrah T, Rao M, Kapata N, Azhar EI, Memish ZA, Mfinanga S, Aseffa A, Ippolito G, Migliori GB, Zumla A.

Int J Infect Dis. 2018 Mar 22.

The critically ill patient with tuberculosis in intensive care: Clinical presentations, management and infection control. Otu A, Hashmi M, Mukhtar AM, Kwizera A, Tiberi S, Macrae B, Zumla A, Dünser MW, Mer M. J Crit Care. 2018 Mar 13;45:184-196.

Accelerating the development of therapeutic strategies for drug-resistant tuberculosis. Vjecha MJ, Tiberi S, Zumla A. Nat Rev Drug Discov. 2018 Mar 23.

Urgent need for multi-site controlled trials for CMV pneumonia treatment in African children. Tembo J, Moraleda C, Rojo P, Zumla A, Bates M. Int J Tuberc Lung Dis. 2018 Apr 1;22(4):469-470.

Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis. Rao M, Valentini D, Zumla A, Maeurer M. Int J Infect Dis. 2018 Mar 2;69:78-84.

Is there sufficient evidence to repeal three decades of clinical research on chronic hepatitis C? Ippolito G, Zumla A, Lanini S. Clin Microbiol Infect. 2018 Jan 8.

Relationship Between Viremia and Specific Organ Damage in Ebola Patients: A Cohort Study. Lanini S, Portella G, Vairo F, Kobinger GP, Pesenti A, Langer M, Kabia S, Brogiato G, Amone J, Castilletti C, Miccio R, Capobianchi MR, Strada G, Zumla A, Di Caro A, Ippolito G; INMI-EMERGENCY EBOV Sierra Leone Study Group. Clin Infect Dis. 2018 Jan 6;66(1):36-44.